Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
Part of Heart & circulation clinical trials.
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hypertrophic cardiomyopathy (a thickened heart muscle).
- Your type is non-obstructive (the thickened muscle doesn't block blood flow).
- You have symptoms like shortness of breath or chest discomfort with activity (NYHA class II or III).
- You are able to do an exercise test on a treadmill or bike.
- Your symptoms are not mainly caused by another condition (like lung disease or severe anemia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
This trial tests an investigational medicine called CRD-4730 (taken as a pill) to see if it can improve heart function and symptoms in people with heart failure and a reduced pumping ability. It may help you feel better and slow the progression of your condition.
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
This trial tests a new medicine, NT-88, for people with a type of heart failure where the heart's pumping ability is moderately reduced (LVEF 41-49%). It aims to see if the treatment is safe and helps improve symptoms like shortness of breath and fatigue.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
Hear when a new Non-obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.